Sangamo Therapeutics, Inc. (SGMO)
OTCMKTS · Delayed Price · Currency is USD
0.1851
+0.010785 (6.19%)
At close: May 26, 2026
Sangamo Therapeutics Employees
Sangamo Therapeutics had 142 employees as of December 31, 2025. The number of employees decreased by 41 or -22.40% compared to the previous year.
Employees
142
Change (1Y)
-41
Growth (1Y)
-22.40%
Revenue / Employee
$243,359
Profits / Employee
-$868,521
Market Cap
76.68M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 142 | -41 | -22.40% |
| Dec 31, 2024 | 183 | -222 | -54.81% |
| Dec 31, 2023 | 405 | -73 | -15.27% |
| Dec 31, 2022 | 478 | 47 | 10.90% |
| Dec 31, 2021 | 431 | 18 | 4.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vaxart | 65 |
| Oncotelic Therapeutics | 43 |
| Nuo Therapeutics | 10 |
| Provectus Biopharmaceuticals | 6 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
Sangamo Therapeutics News
- 23 hours ago - Sangamo price target lowered to $5 from $10 at H.C. Wainwright - TheFly
- 12 days ago - Sangamo Therapeutics Quarterly report: Q1 2026 - Filings
- 12 days ago - Sangamo Therapeutics Earnings release: Q1 2026 - Filings
- 12 days ago - Sangamo Therapeutics Slides: Q1 2026 - Filings
- 12 days ago - Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results - GlobeNewsWire
- 27 days ago - Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) - GlobeNewsWire
- 4 weeks ago - Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market - GlobeNewsWire
- 2 months ago - Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results - GlobeNewsWire